Navigation Links
Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection

py."

About Anadys

Anadys Pharmaceuticals, Inc., http://www.anadyspharma.com, is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company's programs focus on Toll-Like Receptor-based small molecule product candidates and direct antiviral compounds that inhibit key steps in viral proliferation. The Company has core expertise in medicinal chemistry coupled with structure-based drug design, and is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the believed favorable antiviral, metabolic, pharmacokinetic, and preliminary toxicologic properties of ANA598, the expected timing and plans for filing an IND and the possibility that ANA598 may play an important role in future HCV therapy. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. In particular, the results of in vitro studies and initial in vivo studies may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by other factors. In particular, there is no guarantee that Anadys and Novartis will be able to agree on future development activities for ANA975, that the FDA will lift the clinical hold on th
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor Activity of Natural Killer Cells
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:11/28/2008)... Germany, November 28 German biote...hip in specialized HIV monitoring and,AIDS patien...g countries. In,the year 2008, 2.5 million patien...bust and highly affordable "CyFlow" system, suppor...th HIV/AIDS. Due to introduction of the,Partec in...
(Date:11/26/2008)...nn., Nov. 26 Children w...significantly increased risk of developing mental ...of a Mayo Clinic study published this month in Pe...ademy of Pediatrics. , , The retrospective ... with strabismus (misaligned eyes) and compared th...
(Date:11/25/2008)...ness can improve recovery , , Audio and Web...able on the Mayo Clinic News Blog. Please see the ... ROCHESTER, Minn., Nov. 25 /PRNewswire-USNewswire...e patients don,t think they,re having a stroke -- ...heir condition worsens. The findings appear in the...
(Date:11/25/2008)...NCISCO, Calif., Nov. 25 Proteolix,...of novel therapeutics that target,protein degrada...oday,announced that data from two ongoing Phase 2...ma will be presented at the upcoming 50th Annual M...). Carfilzomib is the first in a new class,of sp...
Breaking Medicine Technology:German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Eye Divergence in Children Triples Risk of Mental Illness 2Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 1Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 2Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 3Fund Manager Joins Board of GSI Securitization Inc 1368 1Fund Manager Joins Board of GSI Securitization Inc 1368 2Billians HealthDATA GM Speaking on Dreamforce 07 Panel 1363 1Billians HealthDATA GM Speaking on Dreamforce 07 Panel 1363 2CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 1CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 2CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 3
...g therapeutic cancer vaccine,trials have yet to sh... immune system to shrink tumors -- yet patients wh...nger and respond,better to subsequent treatment. I...journal of the American Association for Cancer,Res...hers asks a,fundamental question: are we looking a...
...)--Jul 5, 2007 - Australian,biotechnology company ...apricitabine,s controlled, double blinded phase wh...ase IIb trial.,Patients have now progressed into t...) and will continue to receive 800mg,apricitabine ...e.,The Company expects to release results from the...
Other Medicine Technology:From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 2From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 3Avexa's Apricitabine Clinical Trial Update 2
(Date:12/2/2008)...tes Healthy Habits , , NEW YORK, Dec. 2 /P...Bulletin Board: JNPC; "Juniper") Sorpresa! , Am...s network, will premiere its 60-minute live-action...max of the network,s seven-month initiative with M...M EST. , , The multifaceted program promote...
(Date:12/2/2008)... -- Neuralstem Inc.,(NYSE Alternext US: CUR) anno...ion with the China Medical University & Hospit...m,s human spinal cord neural stem cell,therapies....ral Sclerosis (ALS,or Lou Gehrig,s disease) with ...ator. , (Logo: http://www.newscom.com/cgi-...
(Date:12/2/2008)...n Medical Resources (AMR), a,provider of premier ...gnostic,imaging industries, finds that Ortho-McNe...rred quinolone antibiotic among more than half of ...ted States. Quinolone antibiotics are,used to tre...caused by,numerous bacterial pathogens. , ...
(Date:12/2/2008)...ents Will Double by 2017, According to a New Repor...., Dec. 2 Decision Resources, one ... for pharmaceutical and healthcare issues, finds t...-Cilag,s Stelara and Abbott/Eisai,s Humira, will d...to more than double to nearly $5 billion over the ...
Breaking Medicine News(10 mins):Health News:Sorpresa! Premieres Juega Como un MLS Pro 2Health News:Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials 2Health News:Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States 2Health News:Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017 2
...ormal breathing functions. Exposure to atmospheric...eart muscle during exercise in those with heart pr...ure to air pollution// with both heart disease and... the first to show how pollution can restrict the ...
...versity in Boston, a person's degree of inhibition...ies is tied to his or her likelihood of being over...--for example by choosing low-calorie foods--can h...tation to eat, according to lead investigator Dr. ...
...t common encountered among the mountaineers. Docto...rs are affected by altitude sickness and others ar...ung function may increase the risk of high altitud...e pulmonary edema (HAPE), can result when people c...
... consume wine in moderation have healthier lifesty...ther types of alcohol. It is well established tha...e health benefit,// chiefly in the form of reduced... may not be the alcohol itself, but linked lifesty...
Other Medicine News:Health News:Stop and think before you eat 2
Precision near-field imaging combined with the best handling IVUS catheter.
The Medison SonoAce 9900 is a fully digital, NT2000 based ultrasound system, with an integrated workstation that is DICOM compatible, designed for multi-specialty applications including general imagi
Full Digital Color Ultrasound
...armonic Echo technology constructs images using se...rtifacts and noise than fundamental-frequency comp...ogy to transmit distortion-free, fundamental-frequ...equency ultrasound beam is a pure sinusoidal wave,...
Medicine Products: